
Labcorp (LH) Stock
Large lab testing provider for hospitals and drug developers. Here's the price, business snapshot, and what's worth knowing about Labcorp in November 2026.
Laboratory Corp. of America Holdings (LabCorp, ticker LH) is a large clinical diagnostics and healthcare services company providing laboratory testing, diagnostic information, and drug development services to hospitals, physicians and biopharma clients. With a market capitalisation of about $23.6bn, LabCorp earns revenue from fee-for-service testing, contracts with healthcare providers, and outsourced clinical trial services. Key investor considerations include steady structural demand for diagnostics from an ageing population and growing use of personalised medicine, balanced against sensitivity to reimbursement rates, regulatory change and competition. LabCorp’s results can be cyclical—volumes often fluctuate with public-health trends such as respiratory outbreaks—and capital allocation choices and acquisitions affect near-term profitability. Investors should review recent financials, margins, cash flow and valuation, and consider exposure to healthcare reimbursement risk. This information is educational only and not personal financial advice; investors should assess suitability and consult a professional before acting.
Why It’s Moving

Labcorp expands global footprint and secures key diagnostic partnership amid reimbursement headwinds
- Labcorp was selected by OTraces to perform reference laboratory testing for a Florida Department of Health–funded prostate cancer study, reinforcing its role in early detection diagnostics.
- The company announced a collaboration with Grupo Fleury to expand clinical trial operations in Brazil, bringing services closer to research sites and patients to support global studies.
- Chief Financial Officer Julia Wang highlighted strength in the central laboratory business driving third-quarter growth, while noting preparation for a potential reduction in government reimbursement rates.

Labcorp expands global footprint and secures key diagnostic partnership amid reimbursement headwinds
- Labcorp was selected by OTraces to perform reference laboratory testing for a Florida Department of Health–funded prostate cancer study, reinforcing its role in early detection diagnostics.
- The company announced a collaboration with Grupo Fleury to expand clinical trial operations in Brazil, bringing services closer to research sites and patients to support global studies.
- Chief Financial Officer Julia Wang highlighted strength in the central laboratory business driving third-quarter growth, while noting preparation for a potential reduction in government reimbursement rates.
When is the next earnings date for LABCORP HOLDINGS INC (LH)?
Labcorp Holdings has not yet confirmed a specific date for its next earnings release. Based on the historical reporting pattern, where the company typically reports approximately three months after the previous quarter's close, the upcoming report is expected in late January 2027. This anticipated release will cover financial results for the fourth quarter of fiscal year 2026. Investors should monitor official announcements for the precise scheduling and timing details.
Why You’ll Want to Watch This Stock
Diagnostics demand trends
Ageing populations and personalised medicine support long-term demand for testing, though volumes can fluctuate with public-health events and policy changes.
Global service footprint
A broad geographic presence and biopharma contracts diversify revenue, but differing regulations and reimbursement rules across markets add complexity.
Innovation and services
Investments in technology and clinical-trial services may improve margins over time, although competition and pricing pressure can constrain gains.